Form 4: United Therapeutics EVP Paul Mahon Executes Share Tracking Awards Under 10b5-1 Plan
SEC Form 4
Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking awards and disposed of common stock under a pre-arranged 10b5-1 plan.
Summary
- Paul Mahon, the EVP & General Counsel of United Therapeutics, executed share tracking awards on March 6, 2025, under a pre-arranged 10b5-1 plan.
- This plan was established on June 20, 2024.
- Mahon exercised 6,550 share tracking awards at a price of $163.3 and disposed of 6,550 shares of common stock at $307.68.
- Following these transactions, Mahon beneficially owns 36,781 shares of common stock.
- The share tracking awards are non-dilutive cash-settled stock appreciation rights, settled in cash and not convertible into common stock.
- Mahon also acquired 71 shares of common stock on March 4, 2025, under the United Therapeutics Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock transactions by an executive. It doesn't contain any particularly positive or negative news, but the use of a 10b5-1 plan suggests a well-managed and transparent approach.
Positives
- The transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned and transparent approach to stock transactions.
Industry Context
Executive stock transactions are common and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan is a standard practice.
Comparison to Industry Standards
- Executive compensation packages often include stock options, restricted stock units (RSUs), and stock appreciation rights (SARs).
- Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to align executive interests with shareholder value.
- The specifics of these plans vary, but the general structure is similar across the biotechnology industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership.
- The employee stock purchase plan benefits employees by allowing them to acquire company stock.
Key Dates
| Date | Description |
|---|---|
| 03/13/2016 | Date exercisable for Share Tracking Award |
| 06/20/2024 | Date of pre-arranged 10b5-1 plan entered into by the reporting person |
| 03/04/2025 | Date of common stock acquired under the United Therapeutics Employee Stock Purchase Plan |
| 03/06/2025 | Date of transaction for share tracking awards and common stock disposal |
| 03/07/2025 | Date of signature |
| 03/13/2025 | Expiration date for Share Tracking Award |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.